CD8A and neoplasm: Another mutation identified in tumor biopsies of non-responders was the mutation in antigen-presenting protein beta-2-microglobulin (B2M), one of the components of MHC I. This aberration can lead to a loss of surface expression of MHC I and disable a proper CD8+ T-cell recognition [39].